Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Advanced Accelerator Applications

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

Novartis gains rights to PTC’s Huntington’s programme in deal worth up to $2.9bn

The genetic disorder affects one in every 10,000 to 20,000 people in the US

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

- PMLiVE

Novartis and Ratio enter radiotherapeutics partnership worth $745m

The companies will focus on advancing a candidate for SSTR2-expressing tumours

- PMLiVE

Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

- PMLiVE

Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML

Approximately 9,280 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

- PMLiVE

Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

The drug is already approved for certain cases of advanced or metastatic breast cancer

- PMLiVE

Novartis’ Fabhalta recommended by NICE to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD

Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

- PMLiVE

Novartis’ Fabhalta granted FDA approval for rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links